ROMA Ovarian Cancer Advanced Screening Package
-
Price︰HK$1,900
-
Report time: 7 to 10 working days
Test includes︰
- Cancer Antigen 125 (CA 125)
- Human Epididymis Protein 4 (HE4)
- Pelvis Ultrasound (Transabdominal)
Included: Ovary, uterus, urinary bladder.
- Sample: Blood
- Location: Suite 1424-1425, 14/F, Ocean Centre, 5 Canton Road, Tsim Sha Tsui, Kowloon
Who should take this test?
- Female.
- Aged 18 years old or above.
- A relative with a known BRCA1 or BRCA2 mutation.
- One or more relatives with a history of cancer, especially breast, ovarian, prostate or pancreatic cancer.
- Family history of hereditary diseases.
- Women had a cancer diagnosis before the age of 50.
- Women who are appropriate to pay attention to menopause and ovarian cancer.
What is ROMA test for?
The ROMA (Risk of Ovarian Malignancy Algorithm) test is a blood test used to assess the likelihood of a woman having ovarian cancer. The test measures the levels of two biomarkers in the blood: CA-125 and HE4 (Human epididymis protein 4).
CA-125 is a protein that is often elevated in women with ovarian cancer, but it can also be elevated in other conditions such as endometriosis and pelvic inflammatory disease. HE4 is a newer biomarker that has been found to be elevated in many cases of ovarian cancer, including early-stage disease.
The ROMA test combines the levels of CA-125 and HE4 with a woman’s menopausal status to calculate a risk score for ovarian cancer. The test is more accurate in postmenopausal women and is used as an aid in the diagnosis of ovarian cancer, especially in women who have an ovarian mass or other symptoms suggestive of ovarian cancer.
The sensitivity of the ROMA test for detecting ovarian cancer depends on the stage of the cancer. In general, the sensitivity of the ROMA test ranges from 75% to 92%, meaning that the test will correctly identify 75% to 92% of women who have ovarian cancer.
The staging system helps doctors determine the best treatment options for ovarian cancer. Generally, the earlier the stage, the better the prognosis and the more likely the cancer can be treated successfully.
However, it is important to note that the ROMA test is not a definitive diagnostic test for ovarian cancer, and further diagnostic tests, such as imaging and biopsy, may be needed to confirm a diagnosis.
For examples: Ultrasound Scanning.
Ovarian cancer 
Ovarian cancer is a type of cancer that begins in the ovaries, which are the female reproductive organs that produce eggs. It can occur at any age, but it is most common in women over 50.
There are different types of ovarian cancer, but the most common is epithelial ovarian cancer, which originates from the cells that line the surface of the ovaries. Other less common types include germ cell tumours and stromal tumours.
Ovarian cancer can be difficult to detect in its early stages because it often does not cause specific symptoms. As the cancer progresses, symptoms may include:
- Bloating, abdominal or pelvic pain
- Difficulty eating or feeling full quickly
- Changes in bowel or bladder habits.
There are several risk factors that can increase a woman’s likelihood of developing ovarian cancer, including a family history of the disease, certain genetic mutations, and certain reproductive factors such as never having been pregnant or starting menstruation at an early age.
For examples:
- Family history of hereditary breast or ovarian cancer.
- Family history of hereditary non-polyposis colorectal cancer (HNPCC).
Diagnosis of ovarian cancer typically involves imaging tests such as ultrasound or CT scans, as well as blood tests that measure levels of the protein CA-125. A biopsy may be performed to confirm the diagnosis.
Ovarian cancer can be classified into 4 stages:
Stage 1: Cancer is confined to one or both ovaries.
- Stage 1A: Cancer is confined to one ovary, with the tumour limited to the inside of the ovary.
- Stage 1B: Cancer is confined to both ovaries, with the tumour limited to the inside of the ovaries.
Stage 2: Cancer has spread to other parts of the pelvis.
- Stage 2A: Cancer has spread to the uterus or fallopian tubes.
- Stage 2B: Cancer has spread to other organs within the pelvis, such as the bladder or rectum.
Stage 3: Cancer has spread to the peritoneum or lymph nodes.
- Stage 3A: Cancer has spread to the peritoneum.
- Stage 3B: Cancer has spread to lymph nodes within the abdomen or pelvis that are smaller than 2 cm.
- Stage 3C: Cancer has spread to lymph nodes within the abdomen or pelvis that are larger than 2 cm or to other organs within the abdomen.
Stage 4: Cancer has spread to distant organs, such as the liver or lungs.
Treatment for ovarian cancer typically involves surgery to remove as much of the tumour as possible, followed by chemotherapy to kill any remaining cancer cells. The type and extent of surgery and chemotherapy depend on the stage and type of ovarian cancer.
Overall, the prognosis for ovarian cancer depends on the stage of the cancer at the time of diagnosis, with earlier stages having a better prognosis. It is important for women to be aware of their risk factors, and the earlier they detect ovarian cancer, the earlier they can receive treatment.
Booking Procedure
For more details on the program, please click check-up items.
